Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168).
Chia-Jui Yen
No relevant relationships to disclose
Bruno Daniele
No relevant relationships to disclose
Masatoshi Kudo
No relevant relationships to disclose
Philippe Merle
No relevant relationships to disclose
Joong-Won Park
No relevant relationships to disclose
Paul J. Ross
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo
Jean-Marie Peron
No relevant relationships to disclose
Oliver Ebert
No relevant relationships to disclose
Stephen Lam Chan
No relevant relationships to disclose
Ronnie Tung Ping Poon
No relevant relationships to disclose
Massimo Colombo
Consultant or Advisory Role - Roche
Honoraria - Roche
Takuji Okusaka
Consultant or Advisory Role - Chugai Pharma
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Baek-Yeol Ryoo
No relevant relationships to disclose
Beatriz Minguez
No relevant relationships to disclose
Takayoshi Tanaka
Employment or Leadership Position - Chugai Pharma
Stock Ownership - Chugai Pharma
Toshihiko Ohtomo
Employment or Leadership Position - Chugai Pharma
Stock Ownership - Chugai Pharma
Olga Rutman
Employment or Leadership Position - Roche
Stock Ownership - Roche
Ya-Chi Chen
Employment or Leadership Position - Roche
Stock Ownership - Roche
Reuy-min Lee
Employment or Leadership Position - Roche
Stock Ownership - Roche
Ghassan K. Abou-Alfa
Research Funding - Chugai Pharma; Roche